NCT02461992View on ClinicalTrials.gov

Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Hemophilia A
Interventions
DRUG

Intravenous infusions of Xyntha

A single dose 50IU/kg dose of Xyntha administered by intravenous infusion within 10 minutes on Day 1

Trial Locations (2)

100032

Phase I Unit, Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing

100045

Hematology Department,Beijing Children's Hospital, Capital Medical University, Beijing

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02461992 - Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A | Biotech Hunter | Biotech Hunter